CNK enters the week heading into November earnings with a notable split between rising short interest and a borrow market that remains wide open — a setup that tells two different stories about where sentiment actually sits.
Short interest has climbed sharply. Over the past five trading days, the estimated short position grew 12% to reach 7.1% of the free float — roughly 8.2 million shares. That is a meaningful build from the ~7.3 million shares borrowed just one week ago, and it comes as the stock has dropped 6.2% on the week to close at $33.93, extending a 9.2% monthly decline. The direction of travel is clear: bears are adding exposure into weakness.
Yet the borrow market itself tells a calmer story. Availability is extraordinarily loose — around 1,800%, meaning there are roughly eighteen shares available to borrow for every one already shorted. That is the most relaxed the lending pool has been all year; the 52-week low in availability was 216%, hit earlier in the year. Cost to borrow ticked up 28% on the week but remains nominal at just 0.45%. In practical terms, there is no squeeze pressure here. Shorts can build without friction, and the rising SI reflects deliberate positioning rather than forced or speculative piling-in.
Options positioning reinforces the cautious tone. The put/call ratio has climbed to 1.26 — the highest reading of the past year, sitting above its 20-day average of 1.08. The shift is stark: as recently as mid-August, the PCR was running below 0.65, reflecting a much more bullish options market. Since late August, demand for puts has risen steadily, mirroring the stock's deterioration and the short interest build. The two signals are pointing in the same direction.
The Street remains broadly constructive despite the near-term softness, but a crack appeared last month. JP Morgan's David Karnovsky downgraded CNK to Neutral on August 14, cutting the target from $40 to $39 — a meaningful shift from a bellwether that had only raised its target to $40 at the end of July. Macquarie moved the other direction, lifting its Outperform target to $44 on September 2. Most other analysts moved targets higher post-Q2 results in late July, with consensus clustering around $40. The mean target of $40 implies roughly 18% upside from current levels, but the JP Morgan move illustrates that confidence in near-term execution is not universal. The bull case centres on a strong 2026 film slate and international diversification. Bears focus on studio window risk and the pace of the post-pandemic consumption shift toward streaming. EV/EBITDA trades near 8.5x, down slightly over the past month as the stock has re-rated lower, while the P/E has compressed to around 13.5x on the same move.
Ownership is worth noting. Lavaca Capital reported a position of nearly 8.1% of shares in June — a massive 13F entry that appears to be a new position. Orbis Investment Management holds 13.1% and has been a consistent buyer. BlackRock holds 14.6% and added shares as recently as August. Wellington Management trimmed its 13G stake from 8.3% to 6.7% in its August filing. No 13D activist is on the register, and all 13D/G positions are as last disclosed around the 5% threshold.
On the insider front, all recent open-market activity has been sales — and all conducted under pre-arranged 10b5-1 plans, which limits their signal value considerably. CEO Sean Gamble sold shares twice in late August (138,884 shares at $38.19 and 7,191 at $35.99), while CFO Melissa Thomas sold 38,236 shares at $37.53. EVP and General Counsel Michael Cavalier sold 107,296 shares on September 1. The 10b5-1 label on every transaction means these are scheduled disposals rather than expressions of conviction — but the volume is notable, and the sales cluster between $35 and $38, well above where the stock trades today.
Next quarter's earnings arrive on November 6. The August 7 print produced only a modest -0.5% one-day reaction, while the prior release (July 30) triggered a +4.9% day and an 8.8% five-day gain. Whether the stock's recent slide — and the short interest build that has accompanied it — reflects a genuine deterioration in box office expectations or simply post-summer profit-taking will become clearer as the film slate for Q4 takes shape in the weeks ahead.
See the live data behind this article on ORTEX.
Open CNK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
